The Quantity And Quality Of Worldwide New Drug Introductions, 1982-2003

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjo...

Full description

Saved in:

Bibliographic Details
Published in:	Health Affairs Vol. 25; no. 2; pp. 452 - 460
Main Authors:	Grabowski, Henry G, Wang, Y. Richard
Format:	Journal Article
Language:	English
Published:	United States Health Affairs 01-03-2006
Subjects:	Biotechnology Drug Industry Drugs, Investigational - standards Drugs, Investigational - supply & distribution Europe Global Health Humans Investigational New Drug Application - statistics & numerical data Orphan Drug Production United States United States Europe
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0278-2715 1544-5208
DOI:	10.1377/hlthaff.25.2.452